Evidence map›Paper›PMID 40858569›Full record

ArticleNature communications2025

Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-β and tau in patients with Alzheimer's disease.

Kamalini G Ranasinghe, Kiwamu Kudo, Faatimah Syed, Claire Yballa, Joel H Kramer, Bruce L Miller, Katherine P Rankin, Paul A Garcia, Heidi E Kirsch, Keith Vossel and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Excitation-inhibition imbalance links amyloid pathophysiology to cognition in non-demented individuals.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. The Alzheimer's disease risk gene SORL1 is a regulator of excitatory neuronal function.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kamalini G RanasingheMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA. Kamalini.ranasinghe@ucsf.edu.ORCID http://orcid.org/0000-0002-4217-8785
Kiwamu KudoDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5732-7229
Faatimah SyedMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Claire YballaMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Katherine P RankinMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3611-0848
Paul A GarciaEpilepsy Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
Heidi E KirschEpilepsy Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3144-2085
Keith VosselMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
William JagustDepartment of Neuroscience, UC Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-4458-113X
Gil D RabinoviciMemory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3626-4265
Srikantan S NagarajanDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

Funding

Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer S Yokoyama · 2019 to 2026
$36.9M
Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Understanding disorder-specific neural pathophysiology in laryngeal dystonia and voice tremorP50DC019900 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Kristina Simonyan · 2021 to 2026
$11.9M
BRAIN INITIATIVE RESOURCE: DEVELOPMENT OF A HUMAN NEUROELECTROMAGNETIC DATA ARCHIVE AND TOOLS RESOURCE (NEMAR)R24MH120037 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Arnaud Delorme, Amitava Majumdar · 2019 to 2026
$5.5M
The role of the cerebellum in speechR01DC017091 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI John Francis Houde, RICHARD IVRY · 2019 to 2026
$4.5M
Mechanisms of Alzheimer's Disease Progression in the Aging BrainR01AG062542 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI JAGUST, WILLIAM J. · 2019 to 2023
$4.2M
Dynamic Brain Imaging of Speech in Primary Progressive AphasiaR01NS100440 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, John Francis Houde · 2017 to 2026
$3.6M
Early Age-of-Onset AD: Clinical Heterogeneity and Network DegenerationR01AG045611 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RABINOVICI, GIL DAN · 2014 to 2018
$3.1M
Network Modelling of Multimodal Dynamics in Alzheimer’s Disease and DementiaRF1AG062196 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAGARAJAN, SRIKANTAN S., RAJ, ASHISH · 2019 to 2019
$3.0M
Electrophysiological and molecular imaging of early AD progressionR01AG088398 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kamalini Gayathree Ranasinghe · 2024 to 2026
$2.4M
Dynamic Brain Imaging of Speech in Primary Progressive AphasiaRF1NS100440 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA, HOUDE, JOHN FRANCIS · 2023 to 2023
$2.4M
Phenotyping the neural basis of sensorimotor control of speech in 16p11.2 deletion syndromeR01DC021711 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carly Demopoulos, John Francis Houde · 2025 to 2026
$1.4M
Alzheimer's Association AARG-21-849773Larry L. Hillblom Foundation (Larry L. Hillblom Foundation, Inc.) 2019-A-013-SUPNIA NIH HHS K08 AG058749NIA NIH HHS K23 AG038357NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG034570NIA NIH HHS R01 AG045611NIA NIH HHS R01 AG062542NIA NIH HHS R01 AG088398NIA NIH HHS R21 AG077498NIA NIH HHS RF1 AG062196NIDCD NIH HHS P50 DC019900NIDCD NIH HHS R01 DC017091NIDCD NIH HHS R01 DC021711NIDCD NIH HHS R21 DC021557NIMH NIH HHS R24 MH120037NINDS NIH HHS R01 NS100440NINDS NIH HHS RF1 NS100440
6 · The paper itself

Abstract

A growing body of evidence shows that epileptic activity is frequently observed in patients with Alzheimer's disease (AD), implicating underlying excitatory-inhibitory imbalance. The distinction of whether the AD-epileptic phenotype represents a subset of patients or an underdiagnosed manifestation holds major therapeutic implications. Here, we quantified the excitatory-inhibitory imbalance in AD patients using magnetoencephalography and examined the relationships to AD pathophysiology-amyloid-beta and tau, and to epileptic activity. We used two metrics to quantify regional excitatory-inhibitory imbalance distinguishing between local hyperexcitability (Neural excitability, quantified by regional aperiodic spectral slope) and aberrant long-range synaptic input integration (Neural fragility, quantified by regional linear dynamic instability). We found that amyloid-beta correlated with higher neural fragility and higher neural excitability, while tau and hypometabolism uniquely correlated with higher neural excitability. Importantly, the AD-epileptic phenotype showed a distinctive increase in neural fragility. Our findings demonstrate that AD pathophysiology is associated with diverse mechanisms of excitatory-inhibitory imbalance and that AD-epileptic phenotype represents a distinct group of patients with greater impairments in long-range synaptic input integration.

Indexed as

Alzheimer DiseaseAmyloid beta-Peptidestau ProteinsAgedAged, 80 and overBrainEpilepsyFemaleHumansMagnetoencephalographyMaleMiddle AgedAmyloid beta-Peptidestau Proteins

Identifiers

PMID40858569
PMCPMC12381375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.